OLYMPUS
6.5.2021 08:02:32 CEST | Business Wire | Press release
Olympus Corporation (”Olympus” – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) announced today it is targeting carbon neutrality by 2030, while also agreeing with recommendations by the Task Force on Climate-Related Financial Disclosures (TCFD), and adding carbon neutrality and enabling a circular economy to its environmental, societal and governance (ESG) enhancement measures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505006248/en/
Olympus has in place a variety of environmental initiatives across its global operations. However, the company is acutely aware of the damaging effects of climate change on natural ecosystems. For this reason, it has added carbon neutrality and enabling a circular economy as an additional ESG materiality criterion.
In its corporate strategy announced in November 2019, Olympus listed four distinct ESG criteria as material ESG enhancement measures: (1) healthcare access and outcomes; (2) compliance, product quality and safety; (3) responsible supply chain; and (4) diversity and inclusion. To these four will be added the new criterion.
Target of Carbon Neutrality by 2030
Olympus set a target of achieving carbon neutrality by 2030 with zero CO2 emissions from its entire business operation. Olympus has already introduced a wide range of initiatives to reduce CO2 emissions, which since 2010 includes procuring 100% of its electricity requirements from renewable sources where it manufactures in Europe and the U.S.
Going forward, Olympus will continue to improve its manufacturing process and the energy-saving measures to achieve carbon neutrality. At the same time, it will accelerate the efforts to reduce CO2 by switching all the electricity procurement for all of its business operations1 to renewable energy sources by 2030.
Support for the Recommendations of TCFD
The TCFD is an international organization that was established in December 2015 by the Financial Stability Board (FSB) to develop the framework for companies to disclose climate-related risks to financial markets. In 2017, the TCFD issued recommendations for use by companies in disclosing pertinent information about risks and opportunities related to climate change to investors, lenders, insurers and other participants in the market so that they can have a more complete picture when assessing the value of those companies and the risks they face. The initiatives of the TCFD are highly evaluated for encouraging sustainable investments to build an economy which is resilient in the face of climate-related uncertainty. Around 1,900 companies and institutions (as of March 25, 2021) have announced their support of the recommendations by the TCFD. (https://www.fsb-tcfd.org/ )
Olympus’ initiatives to reduce its environmental impact and ensure transparent communication about those initiatives fall under its Environmental Health and Safety Policy. The company actively disseminates information about its environmental activities both internally and externally. This includes identifying and disclosing the environmental impact of its business activities.
Olympus strives to promote a mutual understanding about the importance of ESG materiality with stakeholders. Recognizing that climate change is a major issue that affects business operations, Olympus is advancing activities to deal with environmental risks, contributing to carbon tax and complying with other related regulations. Olympus will continue to advance dialogue with stakeholders, and proactively disclose information based on the TCFD recommendations.
| _____________ | ||
1 |
Excluding small sales offices rented locally |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505006248/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom